ADC Therapeutics Slashes Workforce in Reorganization Focused on Cancer Drug

Dow Jones

Jun 24

ADC Therapeutics is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta.

The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies.

With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl.

The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter.

ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits and other related costs.

The company said it expects to have enough cash runway to last at least until 2028.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 24, 2026 07:48 ET (11:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2645520890"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645520890\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645520890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645520890","market":"us","top_or_hot":-1,"title":"ADC Therapeutics Slashes Workforce in Reorganization Focused on Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta. \n</p>\n<p>\n  The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies. \n</p>\n<p>\n  With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl. \n</p>\n<p>\n  The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter. \n</p>\n<p>\n  ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits and other related costs. \n</p>\n<p>\n  The company said it expects to have enough cash runway to last at least until 2028. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 24, 2026 07:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics Slashes Workforce in Reorganization Focused on Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics Slashes Workforce in Reorganization Focused on Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-24 19:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta. \n</p>\n<p>\n  The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies. \n</p>\n<p>\n  With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl. \n</p>\n<p>\n  The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter. \n</p>\n<p>\n  ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits and other related costs. \n</p>\n<p>\n  The company said it expects to have enough cash runway to last at least until 2028. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 24, 2026 07:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645520890","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645520890","pubTimestamp":1782301680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ADC Therapeutics is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta.The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies.With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl.The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter.ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4080":"零售业房地产投资信托","BK4231":"零售房地产信托","BK4505":"高瓴资本持仓","BK4139":"生物科技","ADCT":"ADC Therapeutics SA","BK4007":"制药","LENZ":"Therapeutics","ADC":"艾格里房产"},"translate_title":"ADC Therapeutics在专注于癌症药物的重组中裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9,"LENZ":1.5,"ADC":1.5},"content_text":"ADC Therapeutics is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta. \n\n\n  The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies. \n\n\n  With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl. \n\n\n  The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter. \n\n\n  ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits and other related costs. \n\n\n  The company said it expects to have enough cash runway to last at least until 2028. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 24, 2026 07:48 ET (11:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}